Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Invested Capital (2017 - 2025)

Arcus Biosciences has reported Invested Capital over the past 9 years, most recently at $730.0 million for Q4 2025.

  • Quarterly results put Invested Capital at $730.0 million for Q4 2025, up 36.96% from a year ago — trailing twelve months through Dec 2025 was $730.0 million (up 36.96% YoY), and the annual figure for FY2025 was $730.0 million, up 36.96%.
  • Invested Capital for Q4 2025 was $730.0 million at Arcus Biosciences, up from $534.0 million in the prior quarter.
  • Over the last five years, Invested Capital for RCUS hit a ceiling of $842.0 million in Q4 2021 and a floor of $462.0 million in Q4 2023.
  • Median Invested Capital over the past 5 years was $623.5 million (2024), compared with a mean of $633.9 million.
  • Biggest five-year swings in Invested Capital: surged 372.7% in 2021 and later fell 29.68% in 2023.
  • Arcus Biosciences' Invested Capital stood at $842.0 million in 2021, then fell by 21.97% to $657.0 million in 2022, then dropped by 29.68% to $462.0 million in 2023, then increased by 15.37% to $533.0 million in 2024, then soared by 36.96% to $730.0 million in 2025.
  • The last three reported values for Invested Capital were $730.0 million (Q4 2025), $534.0 million (Q3 2025), and $646.0 million (Q2 2025) per Business Quant data.